{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:28:46Z","timestamp":1793852926998,"version":"4.6.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ophtha.2020.11.012","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T02:06:42Z","timestamp":1605492402000},"page":"877-888","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Neurodevelopmental Outcomes after Bevacizumab Treatment for Retinopathy of Prematurity"],"prefix":"10.1016","volume":"128","author":[{"given":"Chia-Ying","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0461-8778","authenticated-orcid":false,"given":"Po-Ting","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6114-1769","authenticated-orcid":false,"given":"Po-Nien","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chu Ella","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8247-7018","authenticated-orcid":false,"given":"Tso-Ting","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2020.11.012_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr Res"},{"key":"10.1016\/j.ophtha.2020.11.012_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1053\/j.semperi.2019.05.002","article-title":"Epidemiology of ROP update\u2014Africa is the new frontier","volume":"43","author":"Gilbert","year":"2019","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.ophtha.2020.11.012_bib3","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3928\/23258160-20170630-06","article-title":"The epidemiology of retinopathy of prematurity in the United States","volume":"48","author":"Ludwig","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ophtha.2020.11.012_bib4","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity Randomized Trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.11.012_bib5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2020.11.012_bib6","first-page":"CD009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ophtha.2020.11.012_bib7","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ophtha.2017.09.020","article-title":"Foveal development in infants treated with bevacizumab or laser photocoagulation for retinopathy of prematurity","volume":"125","author":"Vogel","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.11.012_bib8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.11.012_bib9","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2020.11.012_bib10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4161\/org.4.4.7415","article-title":"Role of VEGF in organogenesis","volume":"4","author":"Haigh","year":"2008","journal-title":"Organogenesis"},{"key":"10.1016\/j.ophtha.2020.11.012_bib11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4161\/org.6.2.11686","article-title":"VEGF receptor signaling in vertebrate development","volume":"6","author":"Vieira","year":"2010","journal-title":"Organogenesis"},{"key":"10.1016\/j.ophtha.2020.11.012_bib12","doi-asserted-by":"crossref","first-page":"F170","DOI":"10.1136\/archdischild-2011-301148","article-title":"Are we there yet? Bevacizumab therapy for retinopathy of prematurity","volume":"98","author":"Darlow","year":"2013","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"10.1016\/j.ophtha.2020.11.012_bib13","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-0057","article-title":"Concerns for development after bevacizumab treatment of ROP","volume":"137","author":"Quinn","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.ophtha.2020.11.012_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/pr.2013.204","article-title":"Preterm birth-associated neurodevelopmental impairment estimates at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr Res"},{"key":"10.1016\/j.ophtha.2020.11.012_bib15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","article-title":"Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up","volume":"33","author":"Martinez-Castellanos","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2020.11.012_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment","volume":"11","author":"Lien","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.ophtha.2020.11.012_bib17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3928\/23258160-20180129-07","article-title":"Outcomes of intravitreal bevacizumab and diode laser photocoagulation for treatment-warranted retinopathy of prematurity","volume":"49","author":"Chen","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ophtha.2020.11.012_bib18","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3109\/02713683.2014.941070","article-title":"Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"40","author":"Araz-Ersan","year":"2015","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ophtha.2020.11.012_bib19","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.ophtha.2020.11.012_bib20","first-page":"61","article-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","volume":"22","author":"Kennedy","year":"2018","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.ophtha.2020.11.012_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223972","article-title":"Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment","volume":"14","author":"Chang","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.ophtha.2020.11.012_bib22","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.ophtha.2019.03.048","article-title":"Neurodevelopmental outcomes after intravitreal bevacizumab therapy for retinopathy of prematurity: a prospective case-control study","volume":"126","author":"Fan","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.11.012_bib23","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3537","article-title":"Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment","volume":"144","author":"Natarajan","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.ophtha.2020.11.012_bib24","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41372-019-0420-z","article-title":"Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser","volume":"39","author":"Raghuram","year":"2019","journal-title":"J\u00a0Perinatol"},{"key":"10.1016\/j.ophtha.2020.11.012_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3928\/23258160-20190605-01","article-title":"Neurodevelopmental outcomes comparing bevacizumab to laser for type 1 ROP","volume":"50","author":"Rodriguez","year":"2019","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ophtha.2020.11.012_bib26","series-title":"Bayley Scales of Infant and Toddler Development","author":"Bayley","year":"2006"},{"key":"10.1016\/j.ophtha.2020.11.012_bib27","author":"Wells"},{"key":"10.1016\/j.ophtha.2020.11.012_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ophtha.2020.11.012_bib29","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.ophtha.2020.11.012_bib30","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2020.11.012_bib31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.11.012_bib32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.11.012_bib33","doi-asserted-by":"crossref","first-page":"L555","DOI":"10.1152\/ajplung.00408.2001","article-title":"Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure","volume":"283","author":"Le Cras","year":"2002","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.ophtha.2020.11.012_bib34","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2020.11.012_bib35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.exer.2018.01.020","article-title":"The effect of a single anti-vascular endothelial growth factor injection on neonatal growth and organ development: in-vivo study","volume":"169","author":"Khalili","year":"2018","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2020.11.012_bib36","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/0734282906297199","article-title":"Test review: Bayley, N. (2006). Bayley Scales of Infant and Toddler Development\u2013Third Edition. San Antonio, TX: Harcourt Assessment","volume":"25","author":"Albers","year":"2016","journal-title":"J\u00a0Psychoeduc Assess"},{"key":"10.1016\/j.ophtha.2020.11.012_bib37","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1056\/NEJMoa1905593","article-title":"Lower versus traditional treatment threshold for neonatal hypoglycemia","volume":"382","author":"van Kempen","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2020.11.012_bib38","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1242\/dev.114.2.521","article-title":"Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation","volume":"114","author":"Breier","year":"1992","journal-title":"Development"},{"key":"10.1016\/j.ophtha.2020.11.012_bib39","doi-asserted-by":"crossref","first-page":"11946","DOI":"10.1073\/pnas.182296499","article-title":"Vascular endothelial growth factor (VEGF) stimulates neurogenesis in\u00a0vitro and in\u00a0vivo","volume":"99","author":"Jin","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2020.11.012_bib40","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1083\/jcb.200308040","article-title":"VEGF is a chemoattractant for FGF-2-stimulated neural progenitors","volume":"163","author":"Zhang","year":"2003","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.ophtha.2020.11.012_bib41","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1523\/JNEUROSCI.4445-12.2013","article-title":"Neurogenesis continues in the third trimester of pregnancy and is suppressed by premature birth","volume":"33","author":"Malik","year":"2013","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.ophtha.2020.11.012_bib42","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/j.ophtha.2017.05.007","article-title":"Ad Hoc Group Concerning Neurodevelopment and anti-VEGF. Re: Good: Bevacizumab for retinopathy of prematurity: treatment when pathology is embedded in a normally developing vascular system (Ophthalmology. 2016;123:1843\u20131844","volume":"124","author":"Blair","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.11.012_bib43","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.clp.2018.05.005","article-title":"Biological and social influences on the neurodevelopmental outcomes of preterm infants","volume":"45","author":"Burnett","year":"2018","journal-title":"Clin Perinatol"},{"key":"10.1016\/j.ophtha.2020.11.012_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125769","article-title":"Being small for gestational age: does it matter for the neurodevelopment of premature infants? A cohort study","volume":"10","author":"Bickle Graz","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.ophtha.2020.11.012_bib45","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.pediatrneurol.2014.10.027","article-title":"Neurodevelopmental outcome after extreme prematurity: a review of the literature","volume":"52","author":"Jarjour","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.ophtha.2020.11.012_bib46","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1053\/j.semperi.2016.09.002","article-title":"Early neurodevelopmental outcomes of extremely preterm infants","volume":"40","author":"Rogers","year":"2016","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.ophtha.2020.11.012_bib47","first-page":"96","article-title":"Developmental effects of bevacizumab treatment for retinopathy of prematurity","volume":"56","author":"Shipp","year":"2014","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ophtha.2020.11.012_bib48","first-page":"4321","article-title":"Long-term vision and neurodevelopmental outcomes in laser and bevacizumab-treated infants with retinopathy of prematurity","volume":"56","author":"Li","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2020.11.012_bib49","first-page":"228","article-title":"Follow-up of children with treated retinopathy of prematurity (ROP)","volume":"10","author":"Varendi","year":"2017","journal-title":"J\u00a0Perinat Med"},{"key":"10.1016\/j.ophtha.2020.11.012_bib50","first-page":"3764","article-title":"Long-term growth and systemic outcomes in laser and bevacizumab-treated infants with retinopathy of prematurity","volume":"59","author":"Littlejohn","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2020.11.012_bib51","first-page":"6535","article-title":"Outcomes of intravitreal bevacizumab and laser photocoagulation for treatment of retinopathy of prematurity","volume":"60","author":"Ahmed","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2020.11.012_bib52","first-page":"e18","article-title":"Does the newer anti-VEGF therapy impact neurodevelopmental outcomes more than conventional laser therapy in infants treated for retinopathy of prematurity?","volume":"23","author":"Barbeau","year":"2019","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.ophtha.2020.11.012_bib53","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study","volume":"135","author":"Wallace","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.11.012_bib54","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/bjophthalmol-2017-310408","article-title":"Ultra-low-dose intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case series","volume":"102","author":"Hillier","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.11.012_bib55","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"A\u00a0dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments","volume":"125","author":"Wallace","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.11.012_bib56","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2020.11.012_bib57","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1097\/IAE.0000000000002754","article-title":"Anatomical and functional results of intravitreal aflibercept monotherapy for type 1 retinopathy of prematurity: one-year outcomes","volume":"40","author":"Chen","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2020.11.012_bib58","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity","volume":"256","author":"Huang","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642020310769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642020310769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:10:18Z","timestamp":1758982218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642020310769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0161642020310769"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.11.012","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurodevelopmental Outcomes after Bevacizumab Treatment for Retinopathy of Prematurity","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}